Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 12, 2014, Pages 3446-3454

  Herrin, Douglas M ^a   Coates, Emily E ^a   Costner, Pamela J ^a   Kemp, Troy J ^b   Nason, Martha C ^c   Saharia, Kapil K ^a   Pan, Yuanji ^b   Sarwar, Uzma N ^a   Holman, Lasonji ^a   Yamshchikov, Galina ^a   Koup, Richard A ^a   Pang, Yuk Ying S ^d   Seder, Robert A ^a   Schiller, John T ^d   Graham, Barney S ^a   Pinto, Ligia A ^b   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adaptive immunity; Adjuvant; Human papillomavirus vaccine; Immune signatures; Innate immunity

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY; WART VIRUS VACCINE; CHEMOKINE; CYTOKINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY AVIDITY; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMORAL IMMUNITY; IMMUNOLOGICAL PARAMETERS; INNATE IMMUNITY; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; VIRUS NEUTRALIZATION; ADOLESCENT; BLOOD; IMMUNOLOGY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNITY, INNATE; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84922575278     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34408     Document Type: Article

References (39)

1. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927-35; PMID:20473886; http://dx.doi.org/10.1002/ijc.25396
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
3. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
4. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. lancet Oncol 2012; 13:607-15; PMID:22575588; http://dx.doi.org/10.1016/S1470-2045(12)70137-7
5. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1
6. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
7. Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013; 9:1399-406; PMID:23571174; http://dx.doi.org/10.4161/hv.24340
8. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Natil Cancer Inst 2010; 102:325-39; PMID:20139221; http://dx. doi.org/10.1093/jnci/djp534
9. Stanley M. Potential mechanisms for HPV vaccineinduced long-term protection. Gynecol Oncol 2010; 118:S2-7; PMID:20494220; http://dx.doi.org/10.1016/j.ygyno.2010.04.002
10. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71; PMID:19519255; http://dx.doi.org/10.1086/599988
11. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; http://dx.doi.org/10.4161/hv.5.10.9518
12. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343-58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12. 18281
13. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic nonvaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73; PMID:22048172; http://dx.doi.org/10.4161/hv.7. 12.18282
14. Garcia-Pineres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Viruslike particles. Clin Vaccine immunol 2007; 14: 984-9; PMID:17596432; http://dx.doi.org/10.1128/CVI. 00090-07
15. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-4; PMID:21241731; http://dx. doi.org/10.1016/j.vaccine.2011.01.001
16. Stanley M, Pinto LA, Trimble C. Human Papillomavirus Vaccines - Immune Responses. Vaccine 2012; 30: F83-F7; PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106
17. Schiller JT, Castellsague X, Garland SM. A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 2012; 30:F123-F38; PMID: 23199956; http://dx.doi.org/10.1016/j.vaccine.2012. 04.108
18. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natil Acad Sci U S A 1995; 92:11553-7; PMID:8524802; http://dx.doi.org/10.1073/pnas.92.25.11553
19. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63; PMID:7745754
20. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013; 6:1242-50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
21. Summary of the SAGE April 2014 meeting In: Immunization SAGoESo, ed. http://www.who.int/immunization/sage/meetings/2014/april/report-summary-ap ril-2014/en/: The World Health Organization 2014
22. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Nl Cancer Inst 2010; 102:1653-62; PMID:20944077; http://dx.doi.org/10.1093/jnci/djq384
23. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx. doi.org/10.1016/S1470-2045(11)70287-X
24. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35; PMID:19236279; http://dx.doi.org/10.1086/597307
25. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010; 17:818-27; PMID:20237197; http://dx.doi.org/10.1128/CVI. 00348-09
26. Brink R. The imperfect control of self-reactive germinal center B cells. Curr Opin Immunol 2014; 28C:97-101; PMID:25459000; http://dx.doi.org/10.1016/j.coi.2014. 03.001
27. Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005; 23:3555-64; PMID:15855014; http://dx.doi.org/10.1016/j.vaccine.2005.01.146
28. Moretta L, Webb SR, Grossi CE, Lydyard PM, Cooper MD. Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG. J Exp Med 1977; 146:184-200; PMID:301544; http://dx.doi.org/10.1084/jem.146.1.184
29. Korsholm KS, Petersen RV, Agger EM, Andersen P. Thelper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 2010; 129:75-86; PMID:19824919; http://dx.doi.org/10.1111/j.1365-2567.2009.03164.x
30. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-93; PMID:19247370; http://dx.doi.org/10.1038/nri2510
31. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17:479-U121; PMID:21399646; http://dx. doi.org/10.1038/nm.2306
32. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65:3231-40; PMID:18668203; http://dx.doi.org/10.1007/s00018-008-8228-6
33. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71:2498-507; PMID:12704121; http://dx.doi.org/10.1128/IAI.71. 5.2498-2507.2003
34. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; http://dx.doi.org/10.4049/jimmunol.0901474
35. Moody MA, Santra S, Vandergrift NA, Sutherland LL, Gurley TC, Drinker MS, Allen AA, Xia SM, Meyerhoff RR, Parks R, et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol 2014; 88:3329-39; PMID:24390332; http://dx.doi.org/10.1128/JVI.03309-13
36. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 viruslike particle vaccine clinical trial results. Vaccine 2008; 26 Suppl 10:K53-61; PMID:18847557; http://dx.doi.org/10.1016/j.vaccine.2008.06.002
37. Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. Vaccine 2014; 32:3694-705; PMID:24674663; 10.1016/j.vaccine.2014.03.040
38. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77; PMID:16988008; http://dx.doi.org/10.1128/CVI.00162-06
39. Buck CB, Thompson CD. Production of papillomavirus-based gene transfer vectors. Current protocols in cell biology/editorial board, Juan S Bonifacino; et al 2007; Chapter 26:Unit 26 1.